Physician profile
Kerry Bower
NPI 1922104595
$2,165.12
in general payments reported to CMS, 2019-2025
24 companies · $752 in 2025
The $752 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $144 · 2023: $139 · 2024: $1,131 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.34 |
| Education | $259.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $443.14 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $375.73 | 2024-2025 | Entyvio, Eohilia |
| Abbvie INC. | $342.81 | 2022-2025 | |
| Genzyme Corporation | $159.57 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $143.81 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $90.50 | 2024-2025 | |
| Celgene Corporation | $68.88 | 2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $68.29 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $59.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $54.72 | 2024-2025 | |
| Pfizer INC. | $42.94 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $41.67 | 2022-2024 | Zerbaxa, Dificid |
| Janssen Scientific Affairs, LLC | $33.16 | 2024 | |
| Novo Nordisk INC | $32.95 | 2022-2025 | Wegovy |
| Lilly USA, LLC | $30.29 | 2022-2025 | Omvoh |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $30.13 | 2024 | Terlivaz |
| Biohaven Pharmaceutical Holding Company LTD. | $28.97 | 2022 | |
| Enterra Medical, INC. | $23.23 | 2024 | |
| Seqirus USA INC | $18.74 | 2022 | |
| Aimmune Therapeutics, INC. | $16.73 | 2024 | |
| Exact Sciences Corporation | $16.54 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $15.94 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $13.69 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Bower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.